RxDoctor Payments DataLook up a doctor →

Sheila Sahni, MD

Cardiovascular Disease · Clark, NJNPI 1215251103

Payments from drug & device makers

$109,317in general payments, 2019–2025

Across 493 payments — averaging $221.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$93K
  • Amgen$9K
  • Abbott$986
  • Irhythm Technologies, Inc.$984
  • Boston Scientific$573
  • Cardiovascular Systems Inc.$433
  • plus $5K from 48 others

What the payments were for

  • Consulting fees$1,5351%
  • Speaking & faculty fees$85,57378%
  • Travel & lodging$12,24811%
  • Food & beverage$9,9479%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,317 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$136,966
Medicare patients
236
Services billed
1,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan87$110,122
EliquisApixaban51$54,925
OzempicSemaglutide46$53,365
XareltoRivaroxaban31$42,271
FarxigaDapagliflozin Propanediol40$39,473
Repatha SureclickEvolocumab30$35,171
BrilintaTicagrelor20$19,760
Repatha PushtronexEvolocumab15$17,170
VascepaIcosapent Ethyl13$11,709
Praluent PenAlirocumab20$11,576
Ranolazine ErRanolazine68$6,733
Valsartan54$3,416
Atorvastatin Calcium175$2,652
Metoprolol Succinate182$2,344
Olmesartan Medoxomil45$1,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$372$110,12287 claims
AstraZenecaFarxiga, Brilinta$192$59,23360 claims
PfizerEliquis$279$54,92551 claims
Novo NordiskOzempic$92,621$53,36546 claims
Johnson & JohnsonXarelto$206$42,27131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Clark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →